Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Johnson and Johnson
Mallinckrodt
Express Scripts
McKinsey

Last Updated: August 15, 2022

Investigational Drug Information for SCY-635


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug SCY-635?

SCY-635 is an investigational drug.

There have been 14 clinical trials for SCY-635. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2017.

The most common disease conditions in clinical trials are Candidiasis, Candidiasis, Vulvovaginal, and Candidiasis, Invasive. The leading clinical trial sponsors are Scynexis, Inc., Clinical Network Services (CNS) Pty Ltd, and ethica Clinical Research Inc.

There are one hundred and ninety-seven US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for SCY-635
TitleSponsorPhase
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral FluconazoleScynexis, Inc.Phase 3
Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy SubjectsClinical Network Services (CNS) Pty LtdPhase 1
Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy SubjectsScynexis, Inc.Phase 1

See all SCY-635 clinical trials

Clinical Trial Summary for SCY-635

Top disease conditions for SCY-635
Top clinical trial sponsors for SCY-635

See all SCY-635 clinical trials

US Patents for SCY-635

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SCY-635 See Plans and Pricing 1',4'-thio nucleosides for the treatment of HCV IDENIX PHARMACEUTICALS LLC (Cambridge, MA) See Plans and Pricing
SCY-635 See Plans and Pricing Benzimidazole derivatives Enanta Pharmaceuticals, Inc. (Watertown, MA) See Plans and Pricing
SCY-635 See Plans and Pricing Anti-viral compounds AbbVie Inc. (North Chicago, IL) See Plans and Pricing
SCY-635 See Plans and Pricing Anti-viral compounds AbbVie Inc. (North Chicago, IL) See Plans and Pricing
SCY-635 See Plans and Pricing Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof Merck Sharp & Dohme Corp. (Rahway, NJ) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SCY-635

Drugname Country Document Number Estimated Expiration Related US Patent
SCY-635 European Patent Office EP3004130 2033-06-05 See Plans and Pricing
SCY-635 World Intellectual Property Organization (WIPO) WO2014197578 2033-06-05 See Plans and Pricing
SCY-635 Australia AU2010217797 2029-02-27 See Plans and Pricing
SCY-635 Brazil BRPI1007836 2029-02-27 See Plans and Pricing
SCY-635 Canada CA2753382 2029-02-27 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Johnson and Johnson
Mallinckrodt
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.